Designing a Universal Health Coverage essential benefits package under budget constraints — DALY-based priority setting, WHO-CHOICE thresholds, and the DCP3 efficient frontier
Universal Health Coverage design begins with an unavoidable fact: no country, rich or poor, can afford to fund every possible health intervention immediately for everyone. The Disease Control Priorities, 3rd edition (DCP3, 2017) project ranked hundreds of interventions by cost-effectiveness to define a "highest priority package" achievable even in the lowest-income settings — a evidence base that has shaped WHO guidance and national benefit-package design across dozens of countries.
The Disability-Adjusted Life Year (DALY) combines years of life lost to premature death and years lived with disability into a single metric of disease burden. Cost-effectiveness analysis divides an intervention's total cost by the DALYs it averts, producing a cost-per-DALY-averted figure that allows radically different interventions — a vaccine, a surgical procedure, a chronic disease drug regimen — to be ranked on one common scale.
DCP3's highest-priority package methodology: • Reviewed evidence across nine volumes covering reproductive/maternal/newborn/child health, cancer, cardiovascular and other NCDs, mental health, surgery, and health system strengthening • Identified roughly 100 interventions clearing a very low cost-effectiveness bar suitable for low-income country budgets • Estimated total package cost at $76–112 per capita annually for low-income countries — a benchmark used to argue that a meaningful essential package is fiscally achievable even for the poorest states, not an aspirational luxury • Examples of top-ranked interventions: childhood immunization, oral rehydration therapy, tuberculosis DOTS treatment, insecticide-treated bednets, basic emergency obstetric care
Why ranking precedes budgeting: • Establishing the ranking first, independent of any specific budget number, lets the same evidence base be reused as fiscal space expands or contracts — the frontier in Stage 3 is just this ranked list truncated at whatever budget line applies
The ranked intervention list is only actionable once matched against a realistic budget envelope. Fiscal space for health is shaped by GDP per capita, the share of government spending directed to health, and the balance between domestic revenue and external donor financing — parameters that vary enormously across countries and constrain what any essential package can realistically include.
WHO-CHOICE cost-effectiveness thresholds: • Historically, WHO suggested an intervention costing less than 1x GDP per capita per DALY averted was "highly cost-effective," and up to 3x GDP per capita was "cost-effective" • This rule of thumb has been increasingly critiqued as arbitrary and disconnected from actual budget constraints — a country can only fund what its real fiscal envelope allows, regardless of a threshold derived from GDP • Current WHO guidance favors opportunity-cost-based thresholds: what would otherwise have been funded is displaced by any new intervention, so the real comparator is the next-best use of the same money inside the actual health budget
Determining the envelope in practice: • Domestic government health expenditure as a share of total government budget (the "Abuja target" of 15% for African Union states, rarely met in practice) • External financing — donor grants, development bank loans — which is often earmarked for specific disease programs rather than flexible essential-package financing • Out-of-pocket spending, which UHC design explicitly aims to reduce, since catastrophic health expenditure affects an estimated 800 million people globally, spending over 10% of household budget on health
Country examples of envelope-setting in action: • Thailand's Universal Coverage Scheme (the "30 Baht scheme," launched 2002) used HITAP (Health Intervention and Technology Assessment Program), a DALY-based health technology assessment body, to prioritize which services the fixed capitation budget would cover • Ethiopia's Essential Health Services Package (revised 2019) explicitly costed its intervention list against projected domestic and donor financing to set a feasible envelope rather than an aspirational one
With interventions ranked (Stage 1) and a budget set (Stage 2), package selection becomes a straightforward optimization: add interventions in ascending order of cost per DALY averted until the budget envelope is spent. This produces the cost-effectiveness frontier — the theoretical maximum health gain purchasable for a given level of spending, before any equity adjustment is applied.
The efficient frontier construction:
1. Sort all candidate interventions by cost per DALY averted, ascending 2. Walk down the sorted list, cumulatively summing cost 3. Stop adding interventions once cumulative cost reaches the budget envelope 4. The last (marginal) intervention included sets the "shadow price" of the health budget — the cost-effectiveness ratio of the least cost-effective intervention still worth funding at this budget level
What the frontier gets right: • It guarantees no cheaper, more effective intervention is left unfunded while a more expensive, less effective one is included — a basic consistency check that many real-world benefit packages, built through political negotiation rather than systematic ranking, actually fail • It makes the opportunity cost of adding any new intervention explicit: including an expensive low-yield intervention means displacing something higher up the ranked list
What the frontier misses: • Pure cost-per-DALY optimization has no mechanism for geography, poverty, or historical under-investment — it will systematically favor interventions that are cheap to deliver to accessible, already-served populations • A vaccination campaign reaching a dense urban population costs far less per DALY averted than the identical campaign reaching a remote rural population, even though the health need may be equal or greater in the harder-to-reach group • This is precisely the gap Stage 4 (equity adjustment) is designed to correct — the frontier is the efficiency baseline against which any equity trade-off is measured, not the final answer
A benefits package chosen purely by cost-effectiveness ranking can be technically optimal and still politically and ethically unacceptable if it systematically excludes the populations with the greatest health need simply because they are more expensive to reach. Equity weighting deliberately re-ranks or re-includes interventions serving underserved groups, accepting a measurable reduction in aggregate DALYs averted per dollar in exchange for more equitable distribution of health gains.
Equity-weighting approaches used in practice:
1. Distributional cost-effectiveness analysis (DCEA): • Extends standard cost-effectiveness analysis to track health gains and financial burden separately by socioeconomic quintile • Applies higher weight to a DALY averted in the poorest quintile than the same DALY averted in the richest quintile, reflecting a societal preference for reducing health inequality, not just maximizing aggregate health • Requires disaggregated burden-of-disease and cost data by population subgroup — a significant data demand many LMICs cannot yet fully meet
2. Guaranteed minimum inclusion: • Rather than weighting every DALY, some designs simply guarantee that a fixed share of the budget (e.g. 15–20%) is reserved for interventions targeting defined underserved populations (remote rural districts, urban informal settlements, indigenous communities) regardless of where they would rank on a pure national-average cost-effectiveness list
3. Delivery cost adjustment rather than benefit adjustment: • Recognizes that the same intervention is often more expensive to deliver in hard-to-reach areas (1.5–3x urban delivery cost is a common range for last-mile rural health services) and funds that cost premium explicitly rather than excluding the population because the naive cost-per-DALY looks worse
The consistent finding across country applications of DCEA-informed design is that meaningful equity gains are achievable at a modest aggregate efficiency cost — typically single-digit to low-teens percentage reductions in total DALYs averted — a trade-off many governments and their populations judge acceptable once the distributional consequences of a purely efficiency-driven package are made explicit.
The central lesson of equity-adjusted package design is that "cost-effective" and "equitable" are not the same optimization target, and conflating them silently produces packages that look efficient on paper while systematically under-serving the populations UHC is meant to protect first.
A funded, equity-adjusted package on paper does not automatically translate into services actually reaching people. Coverage projection models the gap between theoretical entitlement and realized access, driven by health workforce density, facility distribution, supply chain reliability, and patient-side barriers like distance and out-of-pocket costs that persist even under nominal UHC.
Coverage projection layers three constraints on top of the selected package:
1. Health workforce capacity: • WHO's benchmark threshold of 4.45 skilled health workers (doctors, nurses, midwives) per 1,000 population is associated with reasonable service coverage; many low-income countries remain well below this • A package that entitles the population to a service the workforce cannot physically deliver at scale produces a coverage ceiling independent of financing
2. Facility and supply chain reach: • Distance to nearest functioning facility, stockout rates for essential medicines, and diagnostic equipment availability all discount nominal coverage • The UHC Service Coverage Index (jointly tracked by WHO and the World Bank as an SDG 3.8.1 indicator) aggregates across reproductive/maternal/child health, infectious disease, NCDs, and service capacity to produce a single 0–100 tracking score per country
3. Demand-side barriers: • Even a fully entitled, well-stocked service goes unused if out-of-pocket costs, opportunity cost of travel/time, or low health literacy deter patients • Effective coverage — the share of the population that both needs and actually receives a quality intervention — is consistently and substantially lower than nominal entitlement coverage, with gaps of 20–40 percentage points common in weaker health systems
Coverage projection therefore converts the equity-adjusted package (Stage 4) into a realistic delivery forecast, informing where complementary investment in workforce and infrastructure — not just benefit-package financing — is the binding constraint on actually achieving Universal Health Coverage.
The final design question is not whether a package can be launched, but whether it can be sustained. Essential-package pilots frequently succeed with donor or one-off financing and then collapse or stall when that funding cycle ends. Fiscal sustainability assessment asks whether the package can transition to durable domestic financing as the country's revenue base grows.
A fiscal sustainability check examines three forward-looking questions before a package is finalized:
1. Revenue trajectory: • Is projected domestic government health expenditure, driven by GDP growth and the health share of the government budget, on a path to cover the package cost within a defined horizon (commonly 5–10 years), or does it structurally depend on external financing indefinitely? • The Abuja Declaration target of 15% of government budget to health, adopted by African Union member states in 2001, remains unmet by most signatories — a widely cited illustration of the gap between committed and realized domestic financing
2. Donor dependency ratio: • Packages where more than roughly 30–40% of financing comes from external donors carry meaningfully higher discontinuity risk — donor priorities, global health financing cycles, and geopolitical shifts can abruptly change available funding in ways a domestic tax base does not • Sustainable design favors phasing donor-funded pilot interventions into domestically financed lines over a defined transition period, rather than treating donor financing as a permanent budget component
3. Financing mechanism diversification: • Beyond general tax revenue, mechanisms like social health insurance contributions, sin taxes (tobacco, alcohol, sugar-sweetened beverages) earmarked for health, and mandatory contribution schemes (as used in Thailand's and Rwanda's UHC financing mixes) diversify the revenue base and reduce single-point financing risk
A package that fails the sustainability check is not necessarily wrong in its clinical or equity design — but it signals that the given budget envelope from Stage 2 needs to be revisited against a realistic financing horizon before the package is presented as a durable national commitment, rather than a time-limited pilot.